Cancer research
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Cancer research
A recent study published in Surgical Case Reports demonstrates the effectiveness of multidisciplinary treatments in a rare case of pancreatic ductal adenocarcinoma with metastasis. A 49-year-old patient diagnosed with pancreatic cancer responded positively to treatment with olaparib and modified FOLFIRINOX, achieving a pathological complete response after surgery. The patient remains
Cancer research
Researchers at the Yale University School of Medicine have made a significant breakthrough in understanding the role of asparagine-linked glycosylation protein 1 (ALG1) in lung cancer progression. According to a newly published study, ALG1 promotes aggressive phenotypes of lung adenocarcinoma cells by modulating N-linked glycosylation and endoplasmic reticulum (ER)-stress
Cancer research
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Cancer research
Researchers at Nanchang University have made a significant breakthrough in the diagnosis of non-small cell lung cancer (NSCLC) by developing a non-invasive method to predict epidermal growth factor receptor (EGFR) gene mutations. This method uses multi-parameter CT perfusion imaging (CTPI) to analyze blood volume, transit time, and perfusion surface in
Cancer research
A new study has shed light on the genetic alterations and microRNAs (miRNAs) that play a crucial role in lung cancer progression. According to the research, lung cancer is the most frequently diagnosed type of cancer worldwide, with key genetic alterations involving driver gene mutations that significantly enhance cancer aggressiveness.
Cancer research
Research conducted by scientists at Bengbu Medical University has shed new light on the role of long non-coding RNA (lncRNA) FEZF1-AS1 in non-small cell lung cancer (NSCLC) tumorigenesis and ferroptosis. The study found that FEZF1-AS1 promotes NSCLC progression through suppressing ferroptosis by activating the tumor necrosis factor-alpha (TNF-a)/nuclear factor-kappa
Hemoptysis
A recent study published in Annals of Intensive Care has shed light on the changing clinical characteristics, etiologies, and outcomes of severe hemoptysis (SH) in intensive care unit (ICU) patients. The research, conducted at Sorbonne University, analyzed patients admitted for SH between 2009 and 2019 and compared the findings to
Cancer research
Researchers from the University of Tsukuba investigated the outcome of definitive proton beam therapy (PBT) for second primary non-small cell lung cancer occurring in the contralateral lung after pneumonectomy. The study involved 4 patients with squamous cell carcinoma who underwent PBT between January 2006 and December 2019. The patients had
Cancer research
Researchers from the IRCCS Foundation National Cancer Institute in Milan, Italy, have published a study in The Oncologist, a leading oncology journal, highlighting the superiority of dual PD-1/CTLA-4 blockade with nivolumab and ipilimumab in treating metastatic colorectal cancer (mCRC) patients with deficient mismatch repair (dMMR) and/or microsatellite instability-high
Cancer research
Researchers from the First Affiliated Hospital of Anhui Medical University have developed a novel NLR-based prognostic model that effectively stratifies hepatocellular carcinoma (HCC) patients by survival risk. This study aimed to evaluate the prognostic value and biological function of NLR genes in HCC. The researchers analyzed transcriptomic and clinical data
Cancer research
Research conducted at the University of California has estimated that implementation of a $2000 cap for outpatient prescriptions as authorized by the 2022 Inflation Reduction Act (IRA) would generate a meaningful reduction in out-of-pocket costs for high-cost Medicare Part D beneficiaries who received a diagnosis of cancer. The study, published
